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Abstract: Inherited retinal diseases (IRDs) are often associated with variable clinical expressivity (VE)
and incomplete penetrance (IP). Underlying mechanisms may include environmental, epigenetic,
and genetic factors. Cis-acting expression quantitative trait loci (cis-eQTLs) can be implicated
in the regulation of genes by favoring or hampering the expression of one allele over the other.
Thus, the presence of such loci elicits allelic expression imbalance (AEI) that can be traced by massive
parallel sequencing techniques. In this study, we performed an AEI analysis on RNA-sequencing
(RNA-seq) data, from 52 healthy retina donors, that identified 194 imbalanced single nucleotide
polymorphisms(SNPs) in 67 IRD genes. Focusing on SNPs displaying AEI at a frequency higher
than 10%, we found evidence of AEI in several IRD genes regularly associated with IP and VE
(BEST1, RP1, PROM1, and PRPH2). Based on these SNPs commonly undergoing AEI, we performed
pyrosequencing in an independent sample set of 17 healthy retina donors in order to confirm our
findings. Indeed, we were able to validate CDHR1, BEST1, and PROM1 to be subjected to cis-acting
regulation. With this work, we aim to shed light on differentially expressed alleles in the human
retina transcriptome that, in the context of autosomal dominant IRD cases, could help to explain IP
or VE.
Keywords: Inherited retinal diseases; penetrance; allelic expression imbalance; retina; expressivity
1. Introduction
Inherited retinal diseases (IRDs) are a group of genetic disorders resulting in retinal dysfunction
and/or degeneration which in turn lead to visual impairment and, in some instances, to complete
blindness. Until now, almost 200 genes associated with IRD have been identified with all modes of
inheritance represented (RetNet database https://sph.uth.edu/retnet/, June 2017) [1]. In addition,
IRDs are frequently associated with phenotypic variability in terms of various distinct retinal disease
entities and even inter- and intrafamilial phenotypic heterogeneity in subjects carrying the same
mutation [2,3]. Such diversity is thought to be due to environmental, epigenetic, and genetic factors.
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Focusing on this latter group, features like numerous allelic mutations in the same disease-associated
gene, a diverse set of genes involved in the same disease, and multigenetic factors provide some
molecular answers for the wide range of observed phenotypes. However, several IRD cases have been
reported in which a certain mutation results in affected or unaffected mutation carriers, implicating
incomplete penetrance (IP) or variable expressivity (VE) [2]. The former would refer to those cases in
which a given mutation does not induce the corresponding disease in all mutation carriers, whereas
the latter indicates ranges of symptomatology and severity in carriers of the same genetic condition.
In many instances, the cause and underlying molecular mechanism of IP and VE remains elusive.
To tackle this issue, the concept of modifier genes has been proposed. In this scenario, the pathology
induced by the principle gene defect is worsened or ameliorated at least to some extent by the action
of a secondary gene, for instance by altering the expression of the primary gene or through activating
a surrogate signaling pathway [4–6].
Expression quantitative trait loci (eQTLs) may be alternative mechanisms for IP and VE.
Such eQTLs have the ability to interfere with the expression of genes by affecting the levels
of transcription and translation. From the molecular point of view, eQTLs are mainly single
nucleotide polymorphisms (SNPs) or repetitive elements present within regulatory elements that
can be categorized into two groups depending on their location and effect with respect to a given
gene [7]. trans-eQTLs are situated at distal positions, possibly on a distinct chromosome, equally
influencing the expression of both alleles of the target gene, whereas cis-eQTLs act locally and
differentially in relation to each allele. In particular, cis-eQTLs can alter transcription initiation if
located within promoters, enhancers, or insulators, or affect mRNA stability—for instance, through
regulatory elements located in non-coding regions of transcripts or by inducing differential splicing
(sQTL) [8–10]. Indeed, the presence of these cis-acting regulatory elements entail quantitative transcript
alterations in an allele-specific fashion, also known as allelic expression imbalance (AEI) [11,12].
An example illustrating these concepts in the context of IRDs was established some years ago
in PRPF31-associatedautosomal dominant retinitis pigmentosa (adRP). Asymptomatic carriers of
a dominant mutation were shown to have increased levels of mRNA deduced from the wild type
allele, thus compensating for the lack of function of the mutant allele [13]. Further investigations in
PRPF31 identified that extra copies of a cis-acting minisatellite repeat element (MSR1), adjacent to its
core promoter, repressed gene transcription [14]. Furthermore, a putative trans-acting factor (CNOT3)
has been proposed to act in cis over PRPF31 [15]. Needless to say, this phenomenon could also act on
autosomal recessive or X-linked cases; however, its impact would be hard to assess since compound
heterozygosity or X-chromosome inactivation are respectively characteristic of these cases [16].
Since RNA-sequencing (RNA-seq) has been introduced for genome-wide transcript analysis,
an increasing number of studies apply this technology to address AEI [17,18], progressively replacing
other technologies such as RT-qPCR (real-time quantitative polymerase chain reaction) and genome
wide-SNP (single nucleotide polymorphisms) arrays. The advantage of RNA-seq in comparison to
other technologies is the amount of information that is able to be generated and processed as well as
the automation of the analysis in combination to a relatively low workload. In general, next generation
sequencing and in particular short read applications are not optimally suited for allele quantification,
since it tends to give rise to biased results due to mapping errors. Taking this into account, it is
necessary to validate AEIs obtained from the analysis of RNA-seq data by an independent method
such as pyrosequencing, a well-established method with excellent performance in allele quantification.
Although in recent years the number of publications addressing AEI analysis has thrived,
when it comes to the ophthalmic field, there is still need for a better understanding of how genes
are frequently controlled by cis-regulators in the retina context. To gain insight on this issue, we
reanalyzed RNA-seq data from 50 human healthy retina donors from a previous study by performing
a bioinformatics AEI analysis [19], after analyzing the very limited data of two RNA-seq generated
locally. Follow-up pyrosequencing experiments focusing on the most prominent SNPs gathered in
RNA-seq were carried out on an independent sample-set of 17 human healthy eye donors, from
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which retinal RNA and genomic DNA extracted from the sclera of the same eyecup were available for
validation. All in all, here we provide a comprehensive dataset of SNPs that commonly undergo AEI
in genes associated with IRD in humans; furthermore, we try to hallmark such genes for researchers
and physicians in future investigations and efforts to analyzes and explain IP or VE cases.
2. Materials and Methods
2.1. Human Eye Collection
We collected 17 post-mortem healthy human eyes from donors of German origin (Table S1) for
whom informed consent for research purposes had been obtained with Project No. 105/2009BO1 and
date of votum 13.07.2009. Demographic data including sex and birth date were only available for
11/17 subjects (three female, eight male; age 40–85 years at time of death, mean 68 years). Eyecups were
dissected and retinae were placed into RNA Stabilization Reagent (RNA later, QIAGEN; Hilden,
Germany) to limit RNA degradation with a mean post-mortem interval of 30 h (ranging from 5 to
80 h). Pieces of the sclera were also prepared and frozen at −80◦C for later DNA extraction.
2.2. DNA and RNA Isolation
DNA was obtained from 30 mg of sclera after overnight treatment with Proteinase K (VWR Peqlab,
Darmstadt, Germany) and DNA extraction using a Tissue DNA Mini Kit, PeqGold (VWR Peqlab)
according to the manufacturer’s protocols. Total RNA was isolated from whole retina using an RNeasy
Mini Kit (Qiagen; Hilden, Germany). RNA preparationwas analyzed on a Bioanalyzer 2100 (Agilent
Technologies, Waldbronn, Germany) and RNA integrity number (RIN) was calculated as an estimate
of RNA quality (Table S1).
2.3. RNA-sequencing
To obtain full view of retinal transcriptome, two retina RNA samples from two independent
healthy human eye donors were selected for RNA-seq (Table S1). Libraries were sequenced using
paired-end chemistry, according to the standard operating procedures (SOPs) of the Institute of
Medical Genetics and Applied Genomics, University of Tuebingen, Germany, and Microarray Facility
Tuebingen Services (Tuebingen, Germany). No further details on this process were provided by these
companies. Coherent transcripts were assessed by visual inspection using Integrative Genomics
Viewer (IGV).
2.4. Allelic Expression Imbalance RNA-sequencing Analysis
To conduct the AEI analysis, we used the two initially prepared RNA-seq datasets plus the
50 human RNA-seq retinal samples derived from our previous study (deposited in http://www.ebi.ac.
uk/arrayexpress/experiments/E-MTAB-4377/files/) [19]. These latter 50 samples were sequenced on
an Illumina HiSeq1000 platform (Illumina Inc., San Diego, CA, USA) with paired-end chemistry.
The whole procedure, detailed in Figure 1, was carried out following the GATK (Genome Analysis
Toolkit) best practice (https://software.broadinstitute.org/gatk/documentation/article.php?id=3891).
In brief, trimmed reads were aligned to the human genome (UCSC (University of California Santa
Cruz) genome browser version hg19; https://genome.ucsc.edu/) [20] with two sequential passes of
STAR (ultrafast universal RNA-seq aligner) [21]. Duplicate reads and sorting were performed with
Picard. The splicing-junction re-alignment, local re-alignment, and base quality recalibration were
performed with GATK. The variant calling and variant annotation were carried out with GATK’s
Haplotype Caller and Annovar, respectively.
R and RStudio were used to perform the statistical analysis. We selected the single nucleotide
variants that had a QUAL larger than 225, coverage of at least 20x, each allele supported by at
least two reads, and were also reported in dbSNP (Single Nucleotide Polymorphism database
https://www.ncbi.nlm.nih.gov/projects/SNP/) [22]. For each variant, we calculated the log-ratio
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between alternative and reference read counts. Assuming a normal distribution, the outlier values
were defined as those outside the range of mean±2*SD (standard deviation). Subsequently, we selected
the variants that had outliers in at least one sample. In addition, we kept also variants that had one
outlier sample and at least one moderately imbalanced variant, defined as a linear-ratio outside 0.666
and 1.5 (equivalent to allele percentages in the range of 40–60%).
In a second step, IRD genes selected according to the RetNet database (http://www.sph.uth.tmc.
edu/RetNet/) [1], filtered, and their AEI frequency was calculated for each SNP. With those variants
displaying AEI frequencies higher than 10%, we estimated the orientation of the allelic ratio to find
out whether these SNPs are potentially in linkage disequilibrium (LD) with the causal AEI variant or
haplotype. Next, we calculated the overall strength of the imbalance (absolute allele mean ± standard
error of the mean (SEM)) by orientating all samples towards the allele with the lesser read counts (A)
devided by the allele with most read counts fraction (B). Finally, we estimated kurtosis (and standard
error of kurtosis, SEK) to point out those SNPs for which samples’ allelic ratios are clustered around
the mean value, suggesting a single molecular reason for AEI.
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Figure 1.RNA-seq allelic expression imbalance (AEI) analysis workflow. Detailed are all steps 
contained in the pipeline (see also 2.4. Allelic expression imbalance (AEI) RNA-sequencing analysis). 
This process is subcategorized into three major blocks: Data cleanup, variant discovery, and selection 
of AEI single nucleotide polymorphism (SNPs). QC – quality control, GATK - Genome Analysis 
Toolkit, Indel – insertion/deletion, REF – reference, ALT – alternative, Qual –quality, IRD – inherited 
retinal disease. 
2.5.Single Nucleotide PolymorphismHeterozygosity Confirmation by Sanger Sequencing 
Sanger sequencing of the 17 samples of the testing set was performed to confirm SNP 
heterozygosity out of PCR-amplified genomic scleral DNA prior to pyrosequencing analysis. Primer 
pairs were designed with Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/)[23] and 
checked for potential misalignment with the BLAST-like alignment tool 
(https://genome.ucsc.edu/cgi-bin/hgBlat) [24] (Table S2). PCR fragments were purified (ExoSAP-IT 
enzyme cleanup; USB, Cleveland, OH) andsequenced with dye-termination chemistry (Big Dye 
Terminationchemistry; Applied Biosystems [ABI], Weiterstadt, Germany). Products were separated 
on a DNA capillary sequencer (3100 Genetic Analyzer; ABI, Weiterstadt, Germany) and analyzed 
using Sequence Analysis software (Vers. 5.1; ABI) and sequence trace alignment software (SeqMan; 
DNASTAR, Madison, WI, USA). 
2.6. Pyrosequencing Assay Design 
For AEI verification on an independent sample-set, the pyrosequencing allele quantification 
method was selected. Scleral tissue was used to analyze the SNPs at the DNA allele level. RNA 
extracted from retina was used to check allelic imbalance. All primers and assays were designed 
with PyroMark Assay Design Software 2.0 (QIAGEN, Hilden, Germany) using allele quantification 
(AQ) settings (Table S2). Primers were checked for off-target pairing with the BLAST-like alignment 
tool (BLAT) https://genome.ucsc.edu/cgi-bin/hgBlat/) [24]. Three independent PCRs at DNA level 
and four PCRs from two independent single strand cDNA (complementary DNA) syntheses 
(Transcriptor High Fidelity cDNA Synthesis Kit; Roche, Mannheim, Germany) were performed 
(technical replicates). Streptavidin Sepharose™ High Performance beads (GE Healthcare, Uppsala, 
Figure 1. RNA-seq allelic expression imbalance (AEI) analysis workflow. Detailed are all steps
contained in the pipeline (see also 2.4. Allelic expression i balance (AEI) R A-sequencing analysis).
This process is subcategorized into three major blocks: ata cleanup, variant discovery, and selection
of AEI single nucleotide polymorphis (SNPs). C – quality control, T - Genome Analysis
Toolkit, Indel – insertion/deletion, EF – reference, LT – alternative, ual –quality, IRD – inherited
retinal disease.
2.5. Single Nucleotide PolymorphismHeterozygosity Confirmation by Sanger Sequencing
Sanger sequencing of the 17 samples of the testing set was performed to confirm SNP
heterozygosity out of PCR-amplified genomic scleral DNA prior to pyrosequencing analysis.
Primer pairs were designed with Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-
blast/) [23] and checked for potential misalignment with the BLAST-like alignment tool
(https://genome.ucsc.edu/cgi-bin/hgBlat) [24] (Table S2). PCR fragments were purified (ExoSAP-IT
enzyme cleanup; USB, Cleveland, OH) andsequenced with dye-termination chemistry (Big Dye
Terminationchemistry; Applied Biosystems [ABI], Weiterstadt, Germany). Products were separated
on a DNA capillary sequencer (3100 Genetic Analyzer; ABI, Weiterstadt, Germany) and analyzed
using Sequence Analysis software (Vers. 5.1; ABI) and sequence trace alignment software (SeqMan;
DNASTAR, Madison, WI, USA).
2.6. Pyrosequencing Assay esign
For AEI verification on an independent sample-set, the pyrosequencing allele quantification
method was selected. Scleral tissue was used to analyze the SNPs at the DNA allele level. RNA
extracted from retina was used to check allelic imbalance. All primers and assays were designed with
PyroMark Assay Design Software 2.0 (QIAGEN, Hilden, Germany) using allele quantification (AQ)
settings (Table S2). Primers were checked for off-target pairing with the BLAST-like alignment tool
(BLAT) https://genome.ucsc.edu/cgi-bin/hgBlat/) [24]. Three independent PCRs at DNA level and
four PCRs from two independent single strand cDNA (complementary DNA) syntheses (Transcriptor
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High Fidelity cDNA Synthesis Kit; Roche, Mannheim, Germany) were performed (technical replicates).
Streptavidin Sepharose™ High Performance beads (GE Healthcare, Uppsala, Sweden) were used for
biotinylated strand separation. Pyrosequencing reaction was carried out with PyroMark® Gold Q96
Reagents (QIAGEN, Hilden, Germany) using a PyroMark Q96 Workstation (QIAGEN) and a PyroMark
Q96 ID (QIAGEN).
3. Results
3.1. RNA-sequencing
After collecting post-mortem eyes from 17 human donors not affected by any IRD, two samples
with best RNA quality determined by the RIN were subjected to RNA sequencing. These experiments
generated 54 M and 78 M reads per sample, respectively, with 61% of the reads mapping to the reference
genome (GRCh37/hg19) (Table S1). Visual assessment of AEI candidate SNPs was carried out with
IGV (Table S3, Figure S1). Either because of dubious SNP calling or due to the poor complexity of some
genomic regions, inconsistent read mapping was observed among our list of IRD genes, leading us to
discard SNPs in OPN1LW/MW but also in the 3′UTR of the genes CACNA2D4, CRX, EMC1, PDE6A,
RP1L1, and TUB (Figure S2).
3.2. Allelic expression imbalanceAnalysis on RNA-sequencing Data
Initially, we conducted the bioinformatic analysis on the two locally generated RNA-seq datasets.
The approach described in Section 2.5 gave rise to an average of 93 M reads per sample, with 81% of
them mapping to the reference genome (GRCh37/hg19) (Table S1). After applying filters, we obtained
867 and 842 imbalanced SNPs belonging to 676 and 680 genes for the whole retinal transcriptome,
respectively (Files S1 and S2).
We repeated the same approach with 50 RNA-seq sample-sets previously published by Pinelli et al.
(2016) [19]. In this dataset, we observed 5,856 AEI SNPs in 3,217 genes (File S3). These numbers were
filtered down to 4,596 imbalanced SNPs in 702 genes when excluding single AEI hits.
When focusing exclusively on known IRD genes (Retnet, http://www.sph.uth.tmc.edu/
RetNet/) [1], we detected 194 SNPs in 67 IRD genes (File S4). Out of these, 20 were fully or partially
associated with an autosomal dominant mode of inheritance. Thirty SNPs in these 20 genes displayed
AEI in more than 10% of the samples. SNPs lying in mapping-conflictive regions were excluded,
as mentioned in Section 3.1 (Table 1), and the final list of AEI in IRD genes is listed in Table 1.
We calculated the kurtosis coefficient for every SNP to infer whether the sample ratios found for each
SNP were generally well clustered around the average (Table 1). It was found that the larger the
kurtosis coefficient (larger than three), the more grouped the samples ratios for a given SNP, suggesting
a single molecular cause for the observed imbalance.
Upon this data, we realized that many SNPs, such as rs3130 in PROM1 (21 samples show
allelic ratios higher than 1.5, Table 1) had all or most of their samples’ allelic ratios tilted towards
either below 0.66 or above 1.5 thresholds. This extreme biased finding pointed out that this feature
occurs when the SNP is in LD with the imbalanced causal variant, or when it belongs to a broader
haplotype responsible for AEI. Focusing on autosomal dominant associated IRD genes that we retrieved
from HaploReg v4.1 (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) [25],
the regulatory characteristics of the SNPs in LD with the SNPs shown in Table 1 and Table S5.
Finally, to estimate the strength of the imbalance, we obtained the absolute mean ratio (Table 1)
and the relative allelic percentage (Figure 2). For instance, in BEST1 (rs149698), we found six samples
where the ratio was biased towards >1.5 and only one with a ratio <0.66, making a total of seven
samples showing AEI out of 16 heterozygous samples for this SNP. In this very example, the absolute
mean ratio, calculated upon orientating all samples towards the allele with the lesser read counts (A)
divided by the allele with most read counts fraction (B), was equal to 0.31 ± 0.1168 or 23.1–76.9%
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allelic percentage (Figure 2, Table 1, Table S4). Kurtosis analysis in this very example suggests a diffuse
molecular cause with 0.4463 ± 1.587 (Table 1).
3.3. Pyrosequencing Confirmation
After obtaining a reliable and comprehensive variant list from RNA-seq AEI analysis (Table 1),
we carried on with an independent approach to validate these findings. For this, we used genomic
DNA extracted out of scleral tissue and retinal RNA from 17 different healthy eye donors and checked
for heterozygosity of the candidate variants. For some of the SNPs, the corresponding pyrosequencing
assays were unreliable due to insufficient quality or poor performance of the pyrosequencing probes,
yet for the majority of experiments the allele quantification (AQ) method could be used successfully
(Table S3). For three of these genes (CDHR1, PROM1, BEST1) we could prove AEI at the RNA level,
whereas DNA assessment indicated allele balance either for the candidate SNP and/or analyzed SNPs.
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Figure 2. Representation of the relative allelic percentage (mean ± standard error of the mean or
SEM). Shown are those SNPs in inherited retinal diseases (IRD) genes displaying allelic expression
imbalance (AEI) frequencies higher than 10% in the 52 RNA-seq sample-set. Genes associated with
autosomal dominant inherited IRDs are marked with an asterisk. Allelic balance is delimited within
the 40–60% range.
CDHR1 was the first gene to be analyzed, as it presented the highest AEI frequency according to
our RNA-seq data. SNP rs4933980 showed AEI in all heterozygous samples, whereas at the DNA level
both alleles remained balanced (Figures S3A and S4). According to the RNA-seq data (Figure 2),
the relative allele percentage in AEI samples for rs4933980 lies within the 35.11–64.89% ±0.99
range, whereas in our pyrosequencing analysis the margin was more variable and enlarged to
31.64A–68.36T% ± 0.79.
Following the same procedure, we obtained similar results for two autosomal dominant acting
genes. In the case of PROM1, the pyrosequencing assay for rs3130 showed poor performance.
Nonetheless, we analyzed another SNP, rs7686732, for which we found one heterozygous sample to be
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imbalanced at the RNA level while the remaining were balanced at the DNA level (Figures S3B and S4).
Next, we focused on BEST1. According to the RNA-seq data we generated, HAS13 displayed
AEI throughout the whole transcript (Figure 3, Figure S4). Thus, for this gene we prepared two
pyrosequencing assays focusing on rs149698 and rs1800009. In both cases we detected AEI in
two samples (HAS6 and HAS13) with balanced allelic ratios at the DNA level. For both SNPs
we calculated a mean allele percentage for those samples with AEI obtaining 35.9C–64.1T% and
35.1C–64.9T%, respectively. Yet, we did observed differences in the allelic percentage with respect to
the RNA-seq (23.1–76.9% in rs149698 and 27.7–72.3%in rs1800009).
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Figure 3. Relative allele percentages for SNPs rs149698 and rs1800009in BEST1 at the DNA and RNA
levels. Allelic balance is delimited within the 40–60% range. Error bars correspond to the standard of
the mean (SEM) of allele A. (A) BEST1 rs149698 pyrosequencing r sults. Allele percentages at the DNA
level remained close to 50%. At the RN lev l, there was a bias in HAS6 a d HAS13 in favor of allele T.
(B) BEST1 rs1800009 pyro equencing results. Similar to rs149698, the DNA levels r mained balanced,
whereas at the RNA lev l again HAS6 and HAS13 allele T were overrepresented.
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Table 1. SNPs in inherited retinal diseases (IRD) genes displaying allelic expression imbalance (AEI) frequencies higher than 10% in the 52 RNA-seq dataset.
Highlighted with an asterisk are those genes known to be associated with autosomal dominant IRD. Kurtosis was estimated to stress those SNPs where imbalance was
consistent with a single molecular cause (kurtosis ≥3 indicates closer distribution of the data points towards the mean; standard error of kurtosis is provided as SEK).
Standard error of the mean (SEM) of the allelic ratio was also calculated.
Gene Symbol_ SNP
Samples in Top
Mean± 2*SD
Ratios
Heterozygous
Samples
Allelic
Ratio <0.66
Allelic
Ratio >1.5
Sum
Imbalanced
Samples
AEI Frequency in
Heterozygous
Samples
AEI Frequency
in 52 Samples
Absolute Mean
Allelic Ratio
SEM Allelic
Ratio Kurtosis SEK
ABCA4_rs1762114 7 16 0 8 8 50.0% 15.4% 0.090 0.069 7.636 1.481
ABHD12_rs6107027 1 20 11 1 12 60.0% 23.1% 0.536 0.050 8.709 1.232
BBS5_rs7589199 3 11 5 3 8 72.7% 15.4% 0.354 0.101 −2.19 1.481
*BEST1_rs149698 4 22 1 6 7 31.8% 13.5% 0.310 0.044 0.4463 1.587
*BEST1_1800009 2 20 4 2 6 30.0% 11.5% 0.412 0.091 −1.865 1.741
C3_rs17030 2 29 2 6 8 27.6% 15.4% 0.385 0.087 −0.5529 1.481
CC2D2A_rs4698387 1 17 11 0 11 64.7% 21.2% 0.519 0.032 0.3474 1.279
CDHR1_rs4244947 16 23 21 2 23 100.0% 44.2% 0.247 0.020 0.9735 0.9348
CDHR1_rs4933980 17 21 21 0 21 100.0% 40.4% 0.260 0.016 0.3758 0.9719
CDHR1_rs10509491 1 20 11 0 11 55.0% 21.2% 0.513 0.039 −0.1936 1.279
CDHR1_rs7895270 6 16 10 0 10 62.5% 19.2% 0.308 0.038 1.261 1.334
CDHR1_rs2279229 1 15 7 1 8 53.3% 15.4% 0.541 0.076 7.562 1.481
CNGB1_rs17821448 10 30 1 10 11 36.7% 21.2% 0.158 0.147 11 1.279
*COL11A1_rs2229783 2 19 2 7 9 47.4% 17.3% 0.516 0.058 1.01 1.4
FLVCR1_rs10864027 1 24 5 1 6 25.0% 11.5% 0.454 0.095 1.819 1.741
GRK1_rs9796035 3 21 10 2 12 57.1% 23.1% 0.449 0.058 0.5881 1.232
GRM6_rs11746675 2 32 5 4 9 28.1% 17.3% 0.474 0.074 1.466 1.4
GRM6_rs2067011 1 29 4 3 7 24.1% 13.5% 0.455 0.091 0.6681 1.587
GRM6_rs2071246 3 22 2 4 6 27.3% 11.5% 0.344 0.125 −3.026 1.741
IDH3B_rs5026920 1 12 8 0 8 66.7% 15.4% 0.482 0.045 0.2172 1.481
INPP5E_rs1128874 2 27 8 1 9 33.3% 17.3% 0.500 0.062 5.798 1.154
INPP5E_rs10870194 2 24 0 24 24 100.0% 46.2% 0.092 0.016 0.3604 1.4
INPP5E_rs35763810 3 20 0 6 6 30.0% 11.5% 0.513 0.099 6.436 1.587
MYO7A_rs2276288 3 17 13 1 14 82.4% 26.9% 0.522 0.044 2.193 1.014
PRCD_rs5742903 1 25 7 2 9 36.0% 17.3% 0.457 0.085 0.9821 1.481
PRCD_rs895157 1 17 6 1 7 41.2% 13.5% 0.474 0.069 1.585 1.481
*PROM1_rs3130 8 20 0 19 19 95.0% 36.5% 0.401 0.032 −1.368 1.587
*PRPH2_rs425876 6 14 1 7 8 57.1% 15.4% 0.529 0.057 5.791 1.4
*RP1_rs61739567 2 11 0 8 8 72.7% 15.4% 0.438 0.049 10.86 0.9178
WFS1_rs1046319 1 12 0 7 7 58.3% 13.5% 0.111 0.046 5.809 1.741
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4. Discussion
IRDs represent a genetically very heterogeneous group of diseases with all modes of inheritance
and a large number of genes involved in the development of a pathological phenotype. However, until
recent efforts to better understand retinal transcriptome, little was known about their genomic
regulation. In an attempt to improve our comprehension, we investigated the indirect impact of
common cis-regulatory variants on the whole retinal transcriptome as well as in the context of IRD
genes by means of AEI tracking. To do so, we annotated transcribed SNPs that undergo AEI. Out of
50 RNA-seq samples derived from healthy retina donors, we found 5,856 AEI SNPs in 3,217 genes
(4,596 imbalanced SNPs in 702 genes when excluding single AEI hits (File S3)) [19]. Focusing the
analysis on IRD genes from 52 retinal transcriptomes, we found that 194 SNPs in 67 IRD genes were
imbalanced, although as described in Section 3.1, some of them remain dubious. Further filtering
indicated that 30 SNPs in 20 IRD genes show AEI with frequencies higher than 10% in the sample
population (Figure 2, Table 1).
As a proof of concept, we checked the reliability of our approach by initially confirming that
CDHR1 (Figure S3A), the gene with the highest AEI frequency, indeed shows AEI as confirmed by
pyrosequencing. We further extended this approach to other IRD genes associated with autosomal
recessive but also with COL11A1, PRPH2, PROM1, RP1 and BEST1, known to underlie an autosomal
dominant mode of inheritance. Out of these last five genes, we also validated the results of imbalanced
gene expression in PROM1 and BEST1 (Figure S3B, Figure 2).
Defects in COL11A1 are known to cause Stickler and Marshall syndromes. Among other
symptoms, these are characterized by radial perivascular retinal degeneration, but to our best
knowledge there are no publications specifically reporting variable retinal phenotypes founding
such patients and families [26,27]. In contrast, mutations in PRPH2 are known to cause a variety
of retinal phenotypes and have been described in subjects with autosomal dominant adRP, cone
dystrophy, macular dystrophy, and digenic retinitis pigmentosa. Interestingly, numerous cases with
IP and VE have been reported for this gene [28,29]. Likewise, for PROM1, associated with Stargardt
disease type 4 and dominant macular dystrophy, IP and VE seems to be a common trait linked to
mutations in this gene [30]. RP1 is one of the most prevalent genes related to adRP. As in other genes,
for RP1 IP and VE phenomena have been reported [31]. Finally, mutations in BEST1 give rise to
autosomal recessive and dominant bestrophinopathies, including best disease, autosomal dominant
adult-onset vitelliform macular dystrophy, and autosomal dominant vitreoretinochoroidopathy. For
this gene, the literature also describes various examples with IP or VE [32–34].
As shown in Table 1 and Figure 2, PRPH2 presents with a strong AEI (9.1–98.9% ± 0.0357) with
a quite diverse reason for AEI (kurtosis−1.368, SEK 1.587). In the case of PROM1, the relative allele
percentage is 25.6–74.4% ± 0.017; nonetheless its kurtosis (4.62, SEK 0.9719) indicates a unique source
of AEI. The analysis in RP1 resulted in a 28.8–71.2% ± 0.0256 imbalance percentage with high kurtosis
(10.86, SEK 0.9178), pointing to a single AEI molecular cause. For BEST1 (rs149698), we detected
an allelic percentage of 23.1–76.9% ± 0.044 by means of RNA-seq, levels slightly more extreme than
when confirmed by pyrosequencing (35.9C–64.1T%); however, it seems that there should be several
underlying variants for the observed imbalance (kurtosis 0.4463, SEK1.587).
We found out that the SNPs belonging to the last four genes (among others) are prone to bias
their ratio towards one direction (Table 1). This suggests that the variant or haplotype responsible
for AEI is in LD with the listed SNP. Within this study, we collected all variants and their known
regulatory features in LD (r2 > 0.8) with rs425876 (PRPH2), rs3130 (PROM1), rs61739567 (RP1),and
rs149698 (BEST1) from HaploReg v4.1(Table S5) [25].
To verify whether or not these or other SNPs participate in any cis-regulatory mechanism in these
genes, and to determine the overall gain or loss of transcript quantity, further functional research is
needed. Crossing these results with genotypes of clinical cases may help to analyse and explain the
observed variable phenotype and may in turn be used as prognostic marker.
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5. Conclusions
Phenotypical variability is a well-reported hallmark in IRDs. In this work, we analyzed 52 healthy
retinal transcriptomes to elucidate which genes could contribute to such variability in terms of AEI.
We identified 194 SNPs in 67 IRD genes, out of which 30 SNPs belonging to 20 IRD genes display AEI
in a quite common fashion, with at least 10% of AEI frequency. Interestingly, PRPH2, PROM1, RP1, and
BEST1, genes associated with autosomal dominant forms of IRD that are present in this selective list,
are known to be affected by IP and VE. To prove the relevance of AEI in clinical cases linked to these
genes, further investigation concerning the underlying molecular cause for such frequent phenomena
and their segregation pattern within affected families is still needed. With this comprehensive list of
AEI SNPs, we hope to contribute to the elucidation and understanding of the mechanisms underlying
these phenomena in IRD, and to induce reassessment of clinical cases by ophthalmic clinicians and
researchers in the future.
Supplementary Materials: The following material is available online at www.mdpi.com/2073-4425/8/10/283/s1,
Figure S1: IGV visual inspection on RNA-seq AEI SNP allelic imbalance, Figure S2: IGV visual inspection on
candidate SNP regions, Figure S3: Relative allele percentages for SNPs rs4933980 in CDHR1 andrs7686732,
Figure S4: Pyrograms, Table S1: Biological information of collected eye donor samples, Table S2: List of
pyrosequencing and PCR-Sanger primer, Table S3: RNA-seq AEI SNP list, Table S4: Relative allelic percentage
in IRD genes, Table S5: List of SNPs in LD with AEI candidate SNPs. File S1: HAS4 raw AEI RNA-seq, File S2:
HAS13 raw AEI RNA-seq, File S3: AEI in 50 samples, File S4: IRD SNPs in 52 samples.
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